UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CONTRACT MANUFACTURING

Cambrex

C

Cambrex

Contract ManufacturingEast Brunswick, United States
Visit Website

About Cambrex

Founded in 1981, Cambrex is a leading contract development and manufacturing organisation (CDMO) serving the global pharmaceutical industry, with a specialisation in small molecule active pharmaceutical ingredients (APIs) and finished dosage forms. Its capabilities span the entire drug lifecycle, from early-stage development through commercial manufacture, making it a trusted partner for both innovator and generic pharmaceutical companies worldwide.

Cambrex operates a network of manufacturing and development facilities across North America and Europe, including sites in the United States, Sweden, Italy, and the United Kingdom. This multi-site footprint gives clients geographic flexibility, regulatory coverage across major markets, and resilient supply chain options for critical medicines.

The company's API development and manufacturing services encompass a broad range of chemistries, including highly potent compounds and controlled substances, supported by dedicated containment infrastructure and regulatory expertise. Cambrex also offers drug product services, covering solid oral dosage forms such as tablets and capsules, through its network of finished dose facilities.

In 2019, Cambrex was acquired by private equity firm Permira and taken private, enabling further investment in capacity expansion and technology capabilities. Subsequent acquisitions, including Snapdragon Chemistry and Halo Labs, have strengthened its position in flow chemistry and drug product development respectively, reflecting a strategy of broadening its technical offering to pharmaceutical partners.

Cambrex holds regulatory approvals from agencies including the US FDA and EMA, and its facilities operate under current Good Manufacturing Practice (cGMP) standards across its global network. Further information is available at cambrex.com.

Similar Companies

More in Contract Manufacturing

A

ARTESAN

With more than 75 years of experience serving European and international markets, ARTESAN operates as a full-service contract development and manufacturing organisation within the pharmaceutical industry, guiding clients from initial product concept through to finished, market-ready goods. Since 1996 the company has been a wholly owned subsidiary of the Klosterfrau Group, combining independent operational focus with the resources of an established European healthcare holding. The manufacturing portfolio covers a broad range of solid-dose forms, including granulation, coating, dragees, film tablets, conventional tablets, lozenges and homeopathic preparations, as well as sterile single-use syringes and liquid formulations. This breadth enables ARTESAN to serve partners across multiple therapeutic categories without requiring them to engage separate manufacturing sites for different dosage forms. On the development and compliance side, the company's services extend to product development, product transfer, serialisation and aggregation, analytical services and regulatory submission support. Continuous investment in modern manufacturing and packaging technologies is a stated operating principle, alongside staff development, reflecting a dual commitment to technical capability and scientific expertise at the client-facing level. ARTESAN positions itself on high quality standards, flexible and innovative working practices, and close individual attention to each client relationship, an approach that underpins its long-standing partnerships across European and international pharmaceutical markets. Further information is available at artesan.de.

View profile
A

A&Z Pharmaceutical

Thirty years in pharmaceutical manufacturing have shaped A&Z Pharmaceutical into a contract production partner capable of handling everything from early-stage single-product development through to high-volume commercial output. The company operates a 175,000 square foot facility equipped with cutting-edge manufacturing technology, giving clients access to large-scale, regulated production capacity without the capital burden of building it themselves. End-to-End Manufacturing Services A&Z Pharmaceutical provides end-to-end pharmaceutical manufacturing services covering formulation, production, and supply to clients across the global medicines and dietary supplement market. The integrated offering supports both pharmaceutical product lines and the growing supplement category, reflecting the dual demands placed on contract manufacturers serving health-oriented markets. Quality standards are maintained across every stage, with scientists, technicians, data specialists, managers, and administrative staff collectively forming a workforce of more than 600 employees. The company was founded and is led by Emma Li Xu, whose entrepreneurial record has been recognised through business awards and honours in both the United States and China. Under her leadership, the company's stated mission centres on delivering an uncompromising standard of excellence in pharmaceutical manufacturing, with the broader aim of helping to bring life-changing therapies to patients worldwide. Further information is available at azpharmaceutical.com.

View profile
W

WuXi Biologics

WuXi Biologics operates one of the largest open-access biologics platforms in the world, offering end-to-end services that take a molecule from concept through to commercial manufacture under a single contract research, development and manufacturing organisation. Global CRDMO Platform Founded in 2010 and headquartered in Shanghai, China, WuXi Biologics is listed on the Hong Kong Stock Exchange. The company's integrated model covers discovery, pre-clinical and clinical development, regulatory affairs support, and large-scale biologics manufacturing, spanning monoclonal antibodies, bispecifics, antibody-drug conjugates, fusion proteins, vaccines and cell and gene therapy modalities. Its WuXiUP platform is designed to compress biologics development timelines, enabling partners to move from gene to IND filing on an accelerated schedule. The company maintains a global manufacturing network that includes facilities in China, Ireland, Germany, Singapore and the United States, giving clients commercial-scale GMP capacity across major regulatory jurisdictions. This geographic spread allows multinational pharmaceutical companies as well as emerging biotechs to access compliant manufacturing close to their primary markets. Partnerships Across the Industry WuXi Biologics serves a broad client base that includes global pharmaceutical majors, mid-sized biotechnology companies and academic spin-outs seeking external biologics expertise. The company's contract biologics manufacturing capacity has expanded significantly since its founding, and its client portfolio spans oncology, immunology, rare diseases and infectious disease, reflecting the therapy areas that have driven biologics growth over the past decade. As a publicly traded CRDMO, WuXi Biologics publishes annual reports under Hong Kong Stock Exchange disclosure requirements, providing transparent financial and operational data for partners and investors. Its open-access philosophy, a founding principle, means the company does not compete with its clients by developing proprietary drugs, positioning it as a neutral partner across the industry. Further information is available at wuxibiologics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy